News & Press Releases

Health Law Practice Chair and Health Care Enforcement Defense Co-chair Karen Lovitch was quoted in a recent The Dark Report article on a recent court ruling interpreting the Eliminating Kickbacks in Recovery Act of 2018 (EKRA) and its implications for clinical labs that use independent contractors for marketing. The court decided that while paying independent sales and marketing representatives on a percentage basis is not by itself an EKRA violation, compensation arrangements could still cross the line if marketers exert “undue influence” on physicians.

Peter Saparoff, Chair of Mintz’s Institutional Investor Class Action Recovery Practice, and Associate Sofia Nuño published an article in Bloomberg Law examining how state attorneys general are increasingly applying antitrust and consumer-protection laws to asset managers’ ESG and AI stewardship practices, marking a shift toward more aggressive state-level enforcement beyond federal oversight.

Mintz advised Charlesbank Capital Partners, a middle-market private investment firm, on its acquisition of Q6 Cyber, an intelligence and fraud prevention services provider. 

Mintz represented Breed’s Hill Capital, a multi-family office overseeing approximately $3.5 billion in assets, in its acquisition by Corient, one of the nation’s leading wealth management firms. The transaction enhances Corient’s footprint in New England and advances its ability to deliver personalized fiduciary wealth management services across the region.

Law360 featured commentary from Jason P.W. Halperin in an article about a pharmaceutical industry insider trading case brought by the DOJ. Jason and Elizabeth Platonova represented one of the defendants and negotiated a resolution in which he pled guilty and was sentenced to 15 months in prison.

Mintz advised the placement agents in connection with CAMP4's up to $100 million private placement.  The private placement included upfront gross proceeds of $50 million in exchange for common stock (and pre-funded warrants in lieu of common stock for certain investors). In addition, CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for common stock (and pre-funded warrants for certain investors), subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01.